TY - JOUR
T1 - Update on the safety of second generation antipsychotics in youths
T2 - A call for collaboration among paediatricians and child psychiatrists
AU - Pisano, Simone
AU - Catone, Gennaro
AU - Veltri, Stefania
AU - Lanzara, Valentina
AU - Pozzi, Marco
AU - Clementi, Emilio
AU - Iuliano, Raffaella
AU - Riccio, Maria Pia
AU - Radice, Sonia
AU - Molteni, Massimo
AU - Capuano, Annalisa
AU - Gritti, Antonella
AU - Coppola, Giangennaro
AU - Milone, Annarita
AU - Bravaccio, Carmela
AU - Masi, Gabriele
PY - 2016/5/21
Y1 - 2016/5/21
N2 - During the past decade, a substantial increase in the use of second generation antipsychotics (SGAs) has occurred for a number of juvenile psychiatric disorders, often as off-label prescriptions. Although they were thought to be safer than older, first generation antipsychotics, mainly due to a lower risk of neurological adverse reactions, recent studies have raised significant concerns regarding their safety regarding metabolic, endocrinological and cardiovascular side effects. Aim of this paper is to update with a narrative review, the latest findings on safety of SGAs in youths. Results suggest that different SGAs may present different safety profiles. Metabolic adverse events are the most frequent and troublesome, with increasing evidences of heightened risk for type II diabetes mellitus. Results are discussed with specific emphasis on possible strategies of an active monitoring, which could enable both paediatricians and child psychiatrists to a possible prevention, early detection, and a timely management of such effects.
AB - During the past decade, a substantial increase in the use of second generation antipsychotics (SGAs) has occurred for a number of juvenile psychiatric disorders, often as off-label prescriptions. Although they were thought to be safer than older, first generation antipsychotics, mainly due to a lower risk of neurological adverse reactions, recent studies have raised significant concerns regarding their safety regarding metabolic, endocrinological and cardiovascular side effects. Aim of this paper is to update with a narrative review, the latest findings on safety of SGAs in youths. Results suggest that different SGAs may present different safety profiles. Metabolic adverse events are the most frequent and troublesome, with increasing evidences of heightened risk for type II diabetes mellitus. Results are discussed with specific emphasis on possible strategies of an active monitoring, which could enable both paediatricians and child psychiatrists to a possible prevention, early detection, and a timely management of such effects.
KW - Adolescents
KW - Adverse events
KW - Antipsychotics
KW - Children
UR - http://www.scopus.com/inward/record.url?scp=84969584523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969584523&partnerID=8YFLogxK
U2 - 10.1186/s13052-016-0259-2
DO - 10.1186/s13052-016-0259-2
M3 - Article
AN - SCOPUS:84969584523
VL - 42
JO - Italian Journal of Pediatrics
JF - Italian Journal of Pediatrics
SN - 1720-8424
IS - 1
M1 - 51
ER -